Steven E. Marx - Concepedia

Author

Steven E. Marx

AbbVie (United States)ORCID

Also Known As

I. Mahillo, J. Sayers, K. Takeshita, M. Y. Jeung, S Marx, S. E. Marx, S. Marx, S.E. Marx, Steven E Marx, Steven E. Marx

Publications

924

Citations

H-Index

Concepts

All Affiliations

AbbVie (United States)Abbott (United States)UCLA Medical Center Abbott Fund Saint Louis University

About

Steven E. Marx is an author at AbbVie (United States) specializing in outcomes research, quality improvement, and project management.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	1	1	83
2	Management	1	1	83
3	Medicine	1	1	30
4	Public Health	1	1	83
5	Health Policy	1	1	83

Steven E. Marx

Publications

803

Citations

H-Index

Page 1

	Year	Citations
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings D. Dobrez, Ângelo do Carmo da Silva Mathes, Michael Amdahl, Nephrology Dialysis Transplantation	2004	114
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study Markus Ketteler, Kévin Martin, Myles Wolf, Nephrology Dialysis Transplantation	2012	99
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report William F. McGhan, Maiwenn Al, Jalpa A. Doshi, Value in Health Total Quality ManagementQuality CostEngineeringHealth PolicyQuality Criterion	2009	83
Prevalence of hepatitis G virus and its strain variant, the GB agent, in blood donations and their transmission to recipients W. Kurt Roth, Dorothee Waschk, Steven E. Marx, Transfusion	1997	69
Association of Secondary Hyperparathyroidism with CKD Progression, Health Care Costs and Survival in Diabetic Predialysis CKD Patients Glen T. Schumock, Dennis L. Andress, Steven E. Marx, Nephron Clinical Practice	2009	49
Surgical procedures and their cost estimates among women with newly diagnosed endometriosis: a US database study Mahesh Fuldeore, Kristof Chwalisż, Steven E. Marx, Journal of Medical Economics	2011	42
Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients Glen T. Schumock, Dennis L. Andress, Steven E. Marx, Current Medical Research and Opinion	2008	39
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study M. Ketteler, Kévin Martin, Mario Cozzolino, Nephrology Dialysis Transplantation	2011	35
Estimating the Year Each State in the United States Will Achieve the World Health Organization’s Elimination Targets for Hepatitis C Mark Sulkowski, Wei-Han Cheng, Steven E. Marx, Advances in Therapy	2020	35
Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK Mark Nuijten, Dennis L. Andress, Steven E. Marx, Clinical Drug Investigation Secondary HyperparathyroidismMedicineParathyroid HormoneParathyroid DiseaseParathyroid Gland	2010	30

Page 1